RAPP Q1 2024 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

RAPPRapport Therapeutics, Inc. Common Stock

$1B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$152,000

Operating Income

-$17M

Net Income

-$23M

EPS (Diluted)

$-0.12

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$19M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$206M

Total Liabilities

$246M

Stockholders' Equity

-$40M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$152,000	-$15,000	-913.3%
Operating Income	-$17M	-$5M	-229.3%
Net Income	-$23M	-$6M	-268.8%